Navigation Links
Anadys Pharmaceuticals to Report Second Quarter 2010 Financial Results
Date:7/22/2010

SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report second quarter 2010 financial results on Thursday, July 29, 2010, before the U.S. financial markets open.

Anadys will hold a conference call and webcast on Thursday, July 29, 2010 at 8:30 a.m. Eastern Daylight Time to discuss its second quarter 2010 financial results and to provide an update on the ANA598 development program.  A live webcast of the call will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 28631163.  The webcast and telephone replay will be available through August 12, 2010.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non- nucleoside polymerase inhibitor for the treatment of hepatitis C. In an ongoing Phase II study, the Company has completed 12 weeks of dosing ANA598 added to current standard of care. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement  

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2009, Form 10-Q for the quarter ended March 31, 2010 and Form 8-K filed on May 26, 2010.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anadys Retains Lazard as Strategic Advisor
2. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
3. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
4. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
6. Anadys Pharmaceuticals to Present at the Oppenheimer Healthcare Conference
7. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
9. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
10. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
11. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... February 22, 2017 The ... market are Olympus Corporation, Nikon Corporation, and Leica ... 75% in the overall market in 2015. The ... innovation through result-oriented research and development activities and ... to focus on expanding their business to emerging ...
(Date:2/22/2017)... 22, 2017 According to a new market ... SIMS, CUSCO), Application (Laparoscopy, Colposcopy, Hysteroscopy, D&C, Ablation, Biopsy), & End ... published by MarketsandMarkets, the global market is expected to reach USD ... a CAGR of 7.1% during the forecast period. ... ...
(Date:2/22/2017)... Fla. , Feb. 22, 2017  Corin Group ... System, a device used to treat patients with both ... of shoulder arthritis. The condition, known as cuff tear ... and shoulder. The Humelock Reversed Shoulder ... upper extremities technology company based near Lyon, ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 22, 2017 , ... In a recent article ... context (age, illness and life choices) should be dissociated from medical errors and ... In addition, all too often, studies regarding health system performance in other countries, ...
(Date:2/22/2017)... - NORTHERN CALIFORNIA (PRWEB) , ... February 22, ... ... to expand the pipeline and the number of African American/Black students who want ... students and residents to pursue their careers as physicians in the Oakland/San Francisco ...
(Date:2/21/2017)... ... February 21, 2017 , ... Tripp Lite, a world-leading ... extension cords that meet the most current standards. , The adoption by the ... National Fire Protection Association (NFPA) 101 – Life Safety Code (LSC) and NFPA ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... As recently ... States according to the American Society of Plastic Surgeons. Some patients want to make ... functionality of their nose and improve their breathing ability. The team at usrhinoplasty.org ...
(Date:2/21/2017)... ... , ... Support of value-based care models requires collaboration across all facets of ... solutions, Fogo Data Centers announces the launch of the Fogo Partner Community™. , At ... in which all systems work well, work together, and work together well. In ...
Breaking Medicine News(10 mins):